192 related articles for article (PubMed ID: 23291300)
21. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
22. Challenges in setting permitted daily exposure limits for pharmaceuticals: A review.
Ahuja V; Krishnappa M
Int J Risk Saf Med; 2022; 33(1):49-64. PubMed ID: 34924402
[TBL] [Abstract][Full Text] [Related]
23. Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.
Lovsin Barle E; Winkler GC; Glowienke S; Elhajouji A; Nunic J; Martus HJ
Toxicol Sci; 2016 May; 151(1):2-9. PubMed ID: 27207978
[TBL] [Abstract][Full Text] [Related]
24. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
25. Use of uncertainty factors by the SCOEL in their derivation of health-based occupational exposure limits.
Schenk L; Johanson G
Crit Rev Toxicol; 2010 Oct; 40(9):791-8. PubMed ID: 20860525
[TBL] [Abstract][Full Text] [Related]
26. Harmonization efforts for deriving health-based exposure limits in the pharmaceutical industry - Advancing the current science and practice.
Weideman PA; Pecquet AM; Maier MA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S1-2. PubMed ID: 27531049
[No Abstract] [Full Text] [Related]
27. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products.
Dekant W; Melching-Kollmuss S; Kalberlah F
Regul Toxicol Pharmacol; 2010 Mar; 56(2):135-42. PubMed ID: 19883711
[TBL] [Abstract][Full Text] [Related]
28. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
29. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
Ellis P; Kenyon M; Dobo K
Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
[TBL] [Abstract][Full Text] [Related]
30. Methods for deriving pesticide aquatic life criteria.
TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
[TBL] [Abstract][Full Text] [Related]
31. Performance-based exposure control limits for pharmaceutical active ingredients.
Naumann BD; Sargent EV; Starkman BS; Fraser WJ; Becker GT; Kirk GD
Am Ind Hyg Assoc J; 1996 Jan; 57(1):33-42. PubMed ID: 8588551
[TBL] [Abstract][Full Text] [Related]
32. Occupational toxicology and the control of exposure to pharmaceutical agents at work.
Binks SP
Occup Med (Lond); 2003 Sep; 53(6):363-70. PubMed ID: 14514902
[TBL] [Abstract][Full Text] [Related]
33. Health assessment of phosgene: approaches for derivation of reference concentration.
Gift JS; McGaughy R; Singh DV; Sonawane B
Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
[TBL] [Abstract][Full Text] [Related]
34. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
35. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets.
Poulin P; Arnett R
Regul Toxicol Pharmacol; 2017 Dec; 91():142-150. PubMed ID: 29107009
[TBL] [Abstract][Full Text] [Related]
36. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits.
Dankovic DA; Naumann BD; Maier A; Dourson ML; Levy LS
J Occup Environ Hyg; 2015; 12 Suppl 1(sup1):S55-68. PubMed ID: 26097979
[TBL] [Abstract][Full Text] [Related]
37. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
38. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
39. Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations.
Dolan DG; Naumann BD; Sargent EV; Maier A; Dourson M
Regul Toxicol Pharmacol; 2005 Oct; 43(1):1-9. PubMed ID: 16099564
[TBL] [Abstract][Full Text] [Related]
40. Review of the U.S. Army's health risk assessments for oral exposure to six chemical-warfare agents. Introduction.
J Toxicol Environ Health A; 2000 Mar; 59(5-6):281-526. PubMed ID: 10742829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
